

BMJ Open Pilot study of paediatric regional lung function assessment via X-ray velocimetry (XV) imaging in children with normal lungs and in children with cystic fibrosis

Matthew Bruorton ^{1,2}, Martin Donnelley,¹ Thomas Goddard,^{1,2} Antonia O'Connor,^{3,4} David Parsons,^{1,2} Jessica Phillips,^{1,2} Kristin Carson-Chahhoud,^{1,2} Andrew Tai^{1,2}

To cite: Bruorton M, Donnelley M, Goddard T, *et al.* Pilot study of paediatric regional lung function assessment via X-ray velocimetry (XV) imaging in children with normal lungs and in children with cystic fibrosis. *BMJ Open* 2024;**14**:e080034. doi:10.1136/bmjopen-2023-080034

► Prepublication history for this paper is available online. To view these files, please visit the journal online (<https://doi.org/10.1136/bmjopen-2023-080034>).

Received 19 September 2023
Accepted 07 January 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to
Dr Matthew Bruorton;
matthew.bruorton@adelaide.edu.au

ABSTRACT

Introduction Cystic fibrosis (CF) is a life-limiting autosomal recessive genetic condition. It is caused by mutations in the gene that encodes for a chloride and bicarbonate conducting transmembrane channel. X-ray velocimetry (XV) is a novel form of X-ray imaging that can generate lung ventilation data through the breathing cycle. XV technology has been validated in multiple animal models, including the β -ENaC mouse model of CF lung disease. It has since been assessed in early-phase clinical trials in adult human subjects; however, there is a paucity of data in the paediatric cohort, including in CF. The aim of this pilot study was to investigate the feasibility of performing a single-centre cohort study in paediatric patients with CF and in those with normal lungs to demonstrate the appropriateness of proceeding with further studies of XV in these cohorts.

Methods and analysis This is a cross-sectional, single-centre, pilot study. It will recruit children aged 3–18 years to have XV lung imaging performed, as well as paired pulmonary function testing. The study will aim to recruit 20 children without CF with normal lungs and 20 children with CF. The primary outcome will be the feasibility of recruiting children and performing XV testing. Secondary outcomes will include comparisons between XV and current assessments of pulmonary function and structure.

Ethics and dissemination This project has ethical approval granted by The Women's and Children's Hospital Human Research Ethics Committee (HREC ID 2021/HRE00396). Findings will be disseminated through peer-reviewed publication and conferences.

Trial registration number ACTRN12623000109606.

INTRODUCTION

Cystic fibrosis

Cystic fibrosis (CF) is a life-limiting autosomal recessive genetic condition, with an incidence of approximately 1 in 2500 in the Caucasian population.^{1 2} It is caused by mutations in the gene that encodes for the cystic fibrosis transmembrane conductance regulator (*CFTR*),

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ As a pilot study, the sample size is small, and the aim and design is well suited to the assessment of the feasibility of future X-ray velocimetry (XV) studies in paediatrics and cystic fibrosis.
- ⇒ The cohorts targeted for recruitment have undertaken CT as part of their routine clinical care, limiting the amount of radiation required to undergo XV imaging.
- ⇒ The small study size means that secondary assessments and comparisons of XV and lung function tests may be underpowered.

affecting chloride as well as bicarbonate ion transmembrane channel activity.^{1 3} CF is a multisystem disorder, with CFTR dysfunction causing issues in the lung, pancreas, liver, bowel, sweat glands and vas deferens, among others.

There have been significant advances in the care of CF. With improved treatment of early complications and the use of pancreatic enzyme replacement, the primary morbidity and mortality is now related to pulmonary pathology, including bronchiectasis, small airway obstruction and progressive respiratory failure.^{1 4}

Pulmonary exacerbations

Pulmonary pathology is predominantly driven by inflammation, caused by the inability to clear microorganisms. CFTR dysfunction causes impaired mucociliary clearance; however, multiple other factors also contribute, including mucus tethering and function, impaired innate immunity and increased intrinsic cellular inflammation.^{1 5–7}

Those affected by CF have recurrent exacerbations of disease. Pulmonary exacerbations

are defined symptomatically by increased cough and sputum production and may be associated with respiratory distress, fatigue and reduced exercise tolerance.^{8 9} Investigations including pulmonary function tests, chest imaging, sputum culture and blood inflammatory markers may assist with the clinical decision for treatment initiation and duration.^{1 4 8–10}

Pulmonary assessment and monitoring

There are multiple methods available to assess pulmonary status in CF, including both functional and structural aspects. There are also developments being made in functional lung imaging, with new imaging modalities able to give visual and quantitative assessments of regional lung ventilation.

Pulmonary function testing

The most commonly used pulmonary function test in CF is spirometry. Spirometry is a quick, non-invasive way to assess for airway obstruction or restriction. It requires significant respiratory effort and appropriate technique, meaning it is unsuitable for children less than 5–6 years of age. Reduced forced expiratory volume in 1 s (FEV1) is used as the main indicator of airway obstruction, indicating disease progression or pulmonary exacerbation.^{11 12} Body plethysmography can also be used to measure total lung capacity and residual volume, which can give an indication of gas trapping associated with airway obstruction. These assessments provide a global assessment of lung function. When there is ventilation inhomogeneity, they cannot identify whether there is potentially a compensated abnormality present.¹³

Multiple breath washout is another method of assessing pulmonary function. It has the benefit of being able to be performed in a younger age group due to less dependence on technique.¹⁴ The Lung Clearance Index (LCI) is the most commonly used outcome and reflects the global ventilation inhomogeneity. It has been shown to be associated with evidence of structural lung disease in patients with CF.¹⁵ However, while it is associated with structural disease, it is not able to identify the location of any abnormality.

Structural lung assessment

Structural assessment of the lungs in CF is generally performed through chest X-ray, CT or MRI.

Chest X-ray (CXR) is a quick and commonly used imaging technique. It can assess anatomical changes in the lungs and is generally recommended to be performed annually as part of routine CF care.¹² However, it is limited by low resolution and is not sensitive enough to detect early structural lung changes associated with CF.

High resolution CT is the gold standard for identifying structural lung disease in CF.¹⁶ There have been several scoring systems developed for CF lung disease, aimed at identifying evidence of structural damage including bronchiectasis, mucus plugging, bronchial wall thickening and atelectasis. The Perth-Rotterdam Annotated

Grid Morphometric Analysis method (PRAGMA-CF) is a scoring system developed by Rosenow *et al*, which showed improved correlation between neutrophilic inflammation and CT scores compared with previous methods, as well as stronger relationships between structural changes and trapped air progression.¹⁶ It was also designed to provide reliable quantitative estimates of lung disease in young children, whereas previous methods were predominantly focused on older children and adults. While CT is the gold standard, it is associated with a higher ionising radiation dose than CXR.

MRI of the lung has traditionally been limited, largely due to the technical difficulties produced by low proton density (required for MRI to acquire an appropriate resonance signal) and artefact created by respiratory and cardiac motion.¹⁷ There have been advances in MRI technology to improve lung image quality, with novel MR sequences able to depict some structural changes in CF. However, it is still limited by longer acquisition times and higher expense.

Functional lung imaging

Four dimensional CT

Four-dimensional (4D) CT has a diverse range of methods described in the literature. However, to calculate ventilation metrics, they generally undergo three computational steps, including lung volume delineation, measurement of lung motion and algorithmic calculation of surrogate measures for regional ventilation.^{18 19} The most common algorithms are evaluation of lung volume changes using CT intensity or Hounsfield unit values and deformation vectors.¹⁸

Xenon CT

Xenon is an inert, noble gas. It has been used as an inhalational contrast agent for functional lung imaging due to its X-ray absorption characteristics, being similar to iodine.^{18 20} Xenon CT involves a wash-in phase, where the subject inhales a xenon and oxygen mixture, followed by a period of washout, where they inhale a high oxygen concentration while the radioisotope is exhaled or absorbed. Images captured by CT are subsequently processed into three-dimensional (3D) distribution maps, where ventilation can be qualitatively and quantitatively assessed.^{18 21}

Hyperpolarised gas MRI

Hyperpolarised gas MRI allows an evaluation of both pulmonary anatomy and function, by the visualisation of dynamic ventilation over the course of a respiratory cycle. The use of noble gas contrast agents, such as helium-3 or xenon-129, allows the circumvention of the traditional lack of proton signal in the lung and better image capture.^{17 18 22} Ventilation imaging can provide information about defects (including calculation of the ventilation defect percentage (VDP) the percentage of lung with ventilation below 60% of the mean), and diffusion weighted imaging can be used to calculate the apparent

diffusion coefficient to differentiate between normal and enlarged airspaces.¹⁸ The primary limitations to uptake of hyperpolarised gas MRI is access to expensive hyperpolarising equipment, in addition to an MRI machine and the technical expertise required for testing.

X-ray velocimetry

X-ray velocimetry (XV) is a novel form of X-ray imaging that was designed to collect lung ventilation data. The clinical implementation of this technique uses information collected via X-ray fluoroscopy to track the motion of the distinctive speckle pattern that is created by overlapping alveoli within the lung. In the current clinically available assessments in adults, single breath cine-scans using existing fluoroscopic imaging equipment are captured at five different angles during tidal breathing. When combined with a thoracic CT, the scans are used to construct a 4D map (ie, the 3D volume changes, tracked over time) of regional lung tissue displacement during the breath.^{23 24} This enables creation of a visual map of regional ventilation, derived from the quantitative measures of airflow, and provides metrics such as mean specific ventilation, ventilation heterogeneity (VH) and VDP.²³

XV technology has been validated in multiple animal models, including the β -ENaC mouse model of CF lung disease, in which XV was able to visualise the patchy lung disease and identify regions of reduced airflow.^{24–26} The technique has also shown a strong correlation with direct measurements using pneumotachography and plethysmography in a mouse model of bleomycin-induced pulmonary fibrosis²⁷ and been used to map airflow during high-frequency ventilation.^{28 29} It has since been assessed in early-phase clinical trials in adult human subjects.³⁰ The first clinical validation was performed in a cohort of patients undergoing radiation therapy for various thoracic cancers, excluding lung cancer.³¹ Regional lung ventilation was quantified and compared with spirometry and CT findings at baseline, 4 and 12 months after radiotherapy. Analysis showed correlation between XV ventilation data and both spirometry and CT. XV was also shown to be more sensitive in measuring alterations in regional lung function over time. Changes detected at 4 months via XV were not reflected in spirometry metrics at that time point, but became evident at 12 months post-radiotherapy.³¹

While XV imaging uses X-rays, at the current stage of development it also requires a CT of the chest to provide a structural framework and boundaries for the software. The CT is not required for assessment of ventilation or parenchymal data. With further development, the technique is aimed to no longer require any CT input and acquire all relevant information from fluoroscopy only.

AIM

The aim of this study was to investigate the feasibility of performing XV in paediatric patients with CF and in those

with normal lungs. Before a statistically powered cohort study is undertaken to establish both a normative reference range and a CF diagnostic reference range, a pilot study was deemed necessary to determine if a properly powered study was possible, and to outline the optimal design features.

METHODS AND ANALYSIS

Study design overview

This is a cross-sectional, single-centre, pilot study. It will recruit children aged 3–18 years (inclusive) to have XV lung imaging performed. The study will recruit children without CF with healthy/normal lungs and children with CF. Patients in both cohorts will be required to have had a CT scan within the last 6 months (or as per clinical judgement) or scheduled to have had a CT scan in an upcoming appointment as part of their normal clinical care.

Patients will be recruited at the Women's and Children's Hospital, North Adelaide, Australia. They will undergo a clinical assessment with history and physical examination, undertake an XV scan and perform at least one of spirometry, plethysmography and diffusing capacity, or multiple breath washout. Those with CF will also complete the CFQ-R Cystic Fibrosis questionnaire. The CFQ-R will be applied regularly in a follow-up longitudinal study. Investigators will not be blinded to cohort allocation.

Patient and public involvement

Patients and the public were not involved in the design of this study. Separate to this study, a qualitative assessment of XV will be undertaken and results used to guide future, larger studies.

Ethics and dissemination

Ethical approval has been granted by The Women's and Children's Hospital Human Research Ethics Committee. (HREC ID 2021/HRE00396).

All participants will provide written consent, either individually or by legal guardian if 16 or older, or by their legal guardian if younger than 16.

Findings from this study will be disseminated through peer-reviewed publication and conferences.

Study registration

The study has retrospective registration with the Australian New Zealand Clinical Trial Registry (ANZCTR: 1262000109606) and the Universal Trial Number (UTN: U1111-1287-9096).

Sample selection

Twenty patients will be recruited to both the healthy lung (control) and CF cohorts. A sample size of $n=20$ is within the range recommended for pilot studies to be able to detect adequate effect sizes as would be seen in comparative studies.^{32 33}

For each study arm, potential participants will be identified from medical record reports identifying young people aged 3–18 years who may meet our inclusion criteria. Reports of children who have had a CT scan of their chest within the past 3 months will be compiled by hospital administrators or data custodians of individual departments records for assessment by the study team for potential inclusion in the study.

Arm 1

Arm 1 will include those children with normal lungs. Given children will be required to have a chest CT, specific patient groups have been targeted. These include new-diagnosis oncology patients prior to treatment, physical trauma patients without evidence of lung injury and rheumatology patients without evidence of pulmonary disease. Other patients identified as potentially suitable will be considered on a case-by-case basis.

Arm 2

Arm 2 will include those patients with CF.

Inclusion criteria

- ▶ Aged 3–18 years inclusive at time of consent.
- ▶ CT scan performed within the last 6 months (or as per clinical judgement), or scheduled to have a CT in an upcoming appointment.

Exclusion criteria

- ▶ Pre-existing lung disease in Arm 1, including asthma, interstitial lung disease, etc.
- ▶ In Arm 2, a current or recent (within the past 4–6 weeks) pulmonary exacerbation as diagnosed by CF physician.
- ▶ Currently receiving mechanical ventilation, intensive or critical care.
- ▶ Contraindication to ionising radiation.
- ▶ Urgent clinical treatment precluding the addition of XV imaging.
- ▶ Inability to comply and remain still for period of XV image acquisition.
- ▶ Inability to perform at least one of the pulmonary function tests listed previously.

Intervention

Clinical assessment

Patients will undergo a clinical history and physical examination. The clinical history will include past medical history, current medications and current symptomatology. Physical examination will measure clinical observations and include examination of the cardiac, respiratory and gastrointestinal systems.

X-ray velocimetry scan

An XV scan will be performed in The Women's and Children's Hospital Radiology Department. The XV scan involves fluoroscopic imaging of tidal breathing from five different angles (AP, $\pm 36^\circ$, $\pm 60^\circ$). The images will be sent to 4DMedical, Melbourne, and a report

generated via their X-ray Velocimetry Lung Ventilation Analysis Software (XV LVAS) platform. Tissue expansion is calculated to assess ventilation at a regional level within the lung. Ventilation is determined by measuring the change in volume of a specific lung region during inhalation and dividing it by the volume of that same region at the end of exhalation. This calculation generates a unit called specific ventilation (SV), which quantifies volume changes in mm^3 for each individual lung region. Regions that inflate more have higher SV. The SV measurements are presented as a coloured contour image map of the lungs illustrating the spectrum of ventilation measurements during breathing.

XV LVAS report metrics include the following:

- ▶ Tidal volume (TV)—the volume of air inhaled from start of inspiration to peak inspiration.
- ▶ Mean specific ventilation (MSV)—the mean of specific ventilation across all regions of the lung.
- ▶ Ventilation defect percentage (VDP)—measures the percentage of lung volume that is below 60% of the mean specific ventilation.
- ▶ Ventilation heterogeneity (VH)—measures the overall variability of ventilation across the lung.

Pulmonary function testing

Pulmonary function testing will be performed in the Women's and Children's Hospital Lung Laboratory, a nationally accredited pulmonary function testing centre, under the auspices of the Thoracic Society of Australia and New Zealand.

Multiple breath washout

Eco Medics Exhalysers D equipment will be used to perform nitrogen multiple breath washout testing to generate the LCI.

Spirometry and body plethysmography

Spirometry and DLCO tests will be performed on a Medisoft Spiro Air, as per ERS/ATS standards.^{34 35} Plethysmography testing will be performed using Medisoft bodybox, also as per ERS/ATS standard.³⁶

OUTCOME MEASURES

Primary

The primary outcome measure from this study is to investigate the feasibility of recruiting 20 children without CF and 20 children with CF from our centre to complete an XV scan and the other assessments listed above.

These data will determine if a larger, statistically powered study can be undertaken at this site to evaluate the diagnostic capabilities of XV imaging, which may be able to better measure lung health compared with existing methods.

Secondary

Appropriateness of XV LVAS technology as a clinical assessment for lung function, compared with standard and specialised pulmonary lung function techniques

This will be measured by comparisons of XV-LVAS report metrics to report metrics of existing pulmonary function testing, including spirometry, plethysmography and diffusion capacity, and LCI.

Appropriateness of XV LVAS technology as a clinical assessment for structural lung disease, compared with CT imaging

XV LVAS report metrics will be compared with CT chest evidence of structural lung disease, assessed via PRAGMA-CF scoring.

Identify which participant characteristics should be considered to clinically evaluate lobar ventilation distribution, ventilation heterogeneity and expiratory time constant

This will be determined through visual inspection of characteristic data and identification of potential factors that may influence report metrics. Factors will be considered where correlation trends are observed in continuous and dichotomous variables.

Identify if ongoing assessment of ventilation distribution, ventilation heterogeneity and expiratory time constant is safe and clinically appropriate

This will be determined through a retrospective evaluation of CT scan frequency among the young people with CF, identification of any adverse events during and immediately following XV imaging and preliminary appropriateness of XV LVAS testing.

DATA ANALYSIS

The XV, lung function and CT outcome data obtained from this study will be described by group, using descriptive statistics. Continuous variables will be described using mean and SD, or median and IQR if the distribution is asymmetric. Categorical variables will be presented as numbers and percentages. Demographic variables age, sex, height and weight will also be described by group. Statistical association between outcome measures will be assessed graphically and described using correlation coefficients.

DATA STORAGE

All data for an individual participant will be collected by the principal investigator or their delegated nominees and recorded in the patient record. Participant identification will be through their unique participant study number. All clinical data will be stored as per SA Health data storage guidelines.

Standard clinical lung function data will be collected and stored securely as per WCH guidelines. Each participant's lung function data will be identified by hospital unique record number (URN) initially, then deidentified

using a numerical code before being sent to statisticians for analysis.

Pre-existing radiological data (ie, CT chest) will continue to be stored as per routine clinical data in the WCH Radiology Department, using secure WCH server and SA Health computers.

Deidentified XV LVAS data will be stored in the WCH Respiratory and Sleep Department using the WCH SA Health Network server. Data will be stored for a minimum of 30 years, according to WCH data-retention requirements.

At the conclusion of the study, all hard copy case report forms, signed consent forms and trial data will be archived according to the Respiratory Clinical Trial Unit's Archiving SOP at Iron Mountain.

ADVERSE EVENTS AND ANALYSIS

Lung function testing entails standard procedures that are well established. The testing staff are trained and experienced in recognising and dealing with potential risks, as a normal part of routine testing. Some procedures require special breathing efforts. Known risks are as follows:

- ▶ Dizziness.
- ▶ Feeling short of breath.
- ▶ Coughing.
- ▶ Asthma attack precipitated by deep inhalation.

XV imaging protocol involves exposure to ionising radiation. The radiation dose in the research portion of the study is low, estimated to between 0.52 and 0.83 mSv, equivalent to between 2 and 5 standard CXRs. A detailed analysis of the expected radiation exposure has been undertaken by the assessors in the South Australian Medical Imaging Department prior to study commencement. As per the Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) Code of Practice for the Exposure of Humans to Ionising Radiation for Research Purposes, the radiation exposure is classified as category IIa or 'very-low risk'.³⁷ The radiation dose administered during XV imaging will be monitored and recorded. Exposure settings of the XV scans will be adjusted to administer the lowest practicable dose while still achieving technically useable results.

SPONSORSHIP

This study is supported by 4DMedical, who will provide the XV LVAS reports for patients undergoing XV imaging. 4DMedical have no input into study design, outcome analyses or study conclusions.

CHALLENGES IN STUDY DESIGN

To allow for appropriate XV LVAS mapping and report, a chest CT is currently required to provide the anatomical framework. Given the radiation dose required for CT of the chest region, it is not ethically appropriate to perform a chest CT in children, in addition to that

required for routine clinical care. This is particularly the case in those with healthy lungs where a chest CT assessment is not clinically indicated. This limits the eligible normal lung patient cohort considerably, given the relative clinical reluctance to perform CT in children compared with adults. Some potential cohorts of eligible patients, for example, oncology patients, have routine CT. They also, however, frequently receive agents with known pulmonary side effects. A further limitation is that it will be common to be unable to perform the additional XV imaging and pulmonary function tests on a child in the emotionally difficult period between an oncological diagnosis with routine screening CT and subsequent rapid initiation of treatment.

Pulmonary function testing is dependent on compliance and technique. Children less than 5–6 years of age will be unable to undergo spirometry and plethysmography. In the cohort 5 years and over there can still be technique issues affecting accurate results. This may affect the ability to compare XV imaging with standard lung function metrics in some younger children, however this will not affect the primary study outcome of feasibility.

FUTURE TRIAL CONSIDERATIONS

A feasibility study design is necessary to determine if it is possible to recruit and test children without CF with healthy lungs as well as those with CF to participate in an XV imaging study. This is an important first step towards establishing a statistically powered cohort study. Such a study would evaluate XV LVAS outcomes in children with normal lung function and anatomy that can be used to provide normal reference range data sets against which putative disease states can be examined.

Since XV is a new lung function imaging technology, studies to establish a reference range are a prerequisite before clinical adoption of the technique for diagnosis and monitoring of children with lung pathology.

Author affiliations

¹Adelaide Medical School and The Robinson Research Institute, The University of Adelaide, Adelaide, South Australia, Australia

²Respiratory and Sleep Department, Women's and Children's Health Network, North Adelaide, South Australia, Australia

³Sleep Department, Sydney Children's Hospitals Network, Westmead, New South Wales, Australia

⁴University of New South Wales, Sydney, Sydney, Australia

Contributors MB: Recruitment, draft and review/editing of final manuscript. AT, TG: Concept, study design, ethics submission and approval, recruitment and review/editing of final manuscript. MD: Concept, study design and review/editing of final manuscript. KCC: Concept, design and review/editing of final manuscript. DP: Concept, study design, ethics submission and approval, review/editing of final manuscript. JP: Recruitment and review/editing of final manuscript.

Funding This project is supported by a seed grant from 4DMedical.

Competing interests DP has received remuneration for research advice from 4DMedical. DP and MD have both purchased shares in 4DMedical Ltd.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Matthew Bruorton <http://orcid.org/0000-0003-0737-0947>

REFERENCES

- 1 Elborn JS. Cystic fibrosis. *Lancet* 2016;388:2519–31.
- 2 Ahern Set al. Australian Cystic Fibrosis Data Registry Annual Report 2020. Monash University Department of Epidemiology and Preventative Medicine;2021:22.
- 3 Ong T, Ramsey BW. Cystic Fibrosis. *JAMA* 2023;329:1859.
- 4 Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. *Lancet Respir Med* 2020;8:65–124.
- 5 Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. *Lancet* 2008;372:415–7.
- 6 Keiser NW, Birket SE, Evans IA, et al. Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs. *Am J Respir Cell Mol Biol* 2015;52:683–94.
- 7 Hoegger MJ, Fischer AJ, McMenimen JD, et al. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. *Science* 2014;345:818–22.
- 8 Goss CH. Acute Pulmonary Exacerbations in Cystic Fibrosis. *Semin Respir Crit Care Med* 2019;40:792–803.
- 9 Carter SC, Franciosi AN, O'Shea KM, et al. Acute Pulmonary Exacerbation Phenotypes in Patients with Cystic Fibrosis. *Ann Am Thorac Soc* 2022;19:1818–26.
- 10 Goss CH, Heltshe SL, West NE, et al. A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment. *Am J Respir Crit Care Med* 2021;204:1295–305.
- 11 Stanojevic S, Bilton D, McDonald A, et al. Global Lung Function Initiative equations improve interpretation of FEV1 decline among patients with cystic fibrosis. *Eur Respir J* 2015;46:262–4.
- 12 Kerem E, Conway S, Elborn S, et al. Standards of care for patients with cystic fibrosis: a European consensus. *J Cyst Fibros* 2005;4:7–26.
- 13 Davies J, Sheridan H, Bell N, et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. *Lancet Respir Med* 2013;1:630–8.
- 14 Robinson PD, Latzin P, Ramsey KA, et al. Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society Technical Statement. *Am J Respir Crit Care Med* 2018;197:e1–19.
- 15 Svedberg M, Imberg H, Gustafsson PM, et al. Longitudinal lung clearance index and association with structural lung damage in children with cystic fibrosis. *Thorax* 2023;78:176–82.
- 16 Rosenow T, Oudraad MCJ, Murray CP, et al. PRAGMA-CF. a quantitative structural Lung disease computed tomography outcome in young children with cystic fibrosis. *Am J Respir Crit Care Med* 2015;191:1158–65.
- 17 Dournes G, Walkup LL, Benlala I, et al. The clinical use of Lung MRI in cystic fibrosis: What, Now, How? *Chest* 2021;159:2205–17.
- 18 Karmali D, Sowho M, Bose S, et al. Functional imaging for assessing regional lung ventilation in preclinical and clinical research. *Front Med* 2023;10:1160292.
- 19 Jahani N, Choi S, Choi J, et al. Assessment of regional ventilation and deformation using 4D-CT imaging for healthy human lungs during tidal breathing. *J Appl Physiol* 2015;119:1064–74.
- 20 Ohno Y, Fujisawa Y, Takenaka D, et al. Comparison of xenon-enhanced area-detector CT and krypton ventilation SPECT/CT for assessment of pulmonary functional loss and disease severity in smokers. *AJR Am J Roentgenol* 2018;210:W45–53.
- 21 Kong X, Sheng HX, Lu GM, et al. Xenon-enhanced dual-energy CT lung ventilation imaging: techniques and clinical applications. *AJR Am J Roentgenol* 2014;202:309–17.
- 22 Kolodziej MJ, de Veer MJ, Cholewa M, et al. Lung function imaging methods in Cystic Fibrosis pulmonary disease. *Respir Res* 2017;18:96.
- 23 Parsons D, Donnelley M. Will Airway Gene Therapy for Cystic Fibrosis Improve Lung Function? New Imaging Technologies Can Help Us Find Out. *Hum Gene Ther* 2020;31:973–84.

- 24 Murrie RP, Werdiger F, Donnelley M, *et al.* Real-time in vivo imaging of regional lung function in a mouse model of cystic fibrosis on a laboratory X-ray source. *Sci Rep* 2020;10:447.
- 25 Werdiger F, Donnelley M, Dubsky S, *et al.* Quantification of mucobstructive lung disease variability in mice via laboratory X-ray velocimetry. *Sci Rep* 2020;10:10859.
- 26 Stahr CS, Samarage CR, Donnelley M, *et al.* Quantification of heterogeneity in lung disease with image-based pulmonary function testing. *Sci Rep* 2016;6:29438.
- 27 Fouras A, Allison BJ, Kitchen MJ, *et al.* Altered lung motion is a sensitive indicator of regional lung disease. *Ann Biomed Eng* 2012;40:1160–9.
- 28 Thurgood J, Hooper S, Siew M, *et al.* Functional lung imaging during HFV in preterm rabbits. *PLoS One* 2012;7:e48122.
- 29 Kitchen MJ, Lewis RA, Morgan MJ, *et al.* Dynamic measures of regional lung air volume using phase contrast x-ray imaging. *Phys Med Biol* 2008;53:6065–77.
- 30 Kirkness JP, Dusting J, Eikelis N, *et al.* Association of x-ray velocimetry (XV) ventilation analysis compared to spirometry. *Front Med Technol* 2023;5:1148310.
- 31 Dusting J, Stephens O, Wenger D, *et al.* FIRST-IN-HUMAN VALIDATION OF X-RAY VELOCIMETRY DEMONSTRATES SUPERIOR SENSITIVITY OVER SPIROMETRY AND CT FOR QUANTIFICATION OF REGIONAL LUNG FUNCTION. *Chest* 2020;158:A1393–4.
- 32 Whitehead AL, Julious SA, Cooper CL, *et al.* Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. *Stat Methods Med Res* 2016;25:1057–73.
- 33 Bell ML. New guidance to improve sample size calculations for trials: eliciting the target difference. *Trials* 2018;19.
- 34 Graham BL, Steenbruggen I, Miller MR, *et al.* Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. *Am J Respir Crit Care Med* 2019;200:e70–88.
- 35 Graham BL, Brusasco V, Burgos F, *et al.* 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. *Eur Respir J* 2017;49:1600016.
- 36 Wanger J, Clausen JL, Coates A, *et al.* Standardisation of the measurement of lung volumes. *Eur Respir J* 2005;26:511–22.
- 37 Prof Richard Smart DGD, Wong MS, Marcon MR, *et al.* *Code of Practice: Exposure of Humans to Ionizing Radiation for Research Purposes*. Australian Government: A.R.P.a.N.S. Agency, 2005.